OpenAI said Tuesday that it has acquired Orchestra Bio, a four-year-old startup that makes AI biotech software, according to an announcement on the company's website. Financial terms of the transaction were not disclosed. Orchestra had reportedly raised roughly $20 million as of 2025, with investors including Andreessen Horowitz, Atria, and 8VC.
Orchestra builds AI agents designed to help biotech companies handle the operational details of drug discovery. Those agents assist with tasks such as tracking finances and resolving scheduling problems tied to clinical trials.
OpenAI said it is bringing Orchestra's team and technology into its work on Rosalind, its AI model for life sciences research, as well as Rosalind Workbench, a tool built to help researchers plan experiments and analyze results. OpenAI said Rosalind has already attracted large customers, including Moderna and Novo Nordisk.
The deal reflects a broader pattern among the largest AI labs, namely OpenAI and Anthropic, which are increasingly building software for major industries such as pharmaceuticals. For startups, that trend has fed persistent concern that the labs could introduce new features at any time and turn into direct competitors.
In this instance, Orchestra is being absorbed into OpenAI rather than displaced by it. The acquisition adds a small, venture-backed team to OpenAI's life sciences efforts at a time when the company is courting pharmaceutical customers for Rosalind and Rosalind Workbench.
Orchestra's software addresses the administrative side of drug discovery, an area where biotech firms coordinate budgets and clinical trial logistics alongside scientific work. OpenAI's Rosalind products, by contrast, focus on research planning and analysis.
More company and startup news from TechManNews.
